The role of amifostine as a radioprotector.

Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer

2000 • 809 citations

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1992 • 695 citations

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.

1990 • 474 citations

Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood

2000 • 436 citations

Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study

2000 • 275 citations

Use of radiation with or without WR-2721 in advanced rectal cancer

1992 • 134 citations

Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction

1994 • 111 citations

A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma

2000 • 103 citations

Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.

1998 • 87 citations

Final report on phase i trial of WR-2721 before protracted fractionated radiation therapy

1988 • 79 citations

Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer : an interim report

1997 • 71 citations

Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer

2000 • 70 citations

Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.

1997 • 68 citations

Pharmacokinetics of amifostine: effects of dose and method of administration.

1999 • 58 citations

Radiation Protectors: the Unexpected Benefits

1989 • 57 citations

Advances in three-dimensional treatment planning and conformal dose delivery.

1997 • 49 citations

Clinical status and optimal use of amifostine.

1999 • 46 citations

Protection by WR-2721 of human bone marrow function following irradiation

1986 • 44 citations

Radioprotectors in tumor radiotherapy: factors and settings determining therapeutic ratio

1988 • 30 citations

Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer

1993 • 22 citations

18 Randomized phase III trial of radiation ± amifostine in patients with advanced stage lung cancer

1999 • 20 citations

A Phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies

1992 • 15 citations

The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.

1996 • 6 citations

Assessment of the protective effect of amifostine on radiation induced pulmonary toxicity

2000 • 3 citations